Theravance Completes Enrollment in Phase 3 CYPRESS Study

An announcement from Theravance Biopharma ( (TBPH) ) is now available.

On August 25, 2025, Theravance Biopharma announced the completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study for ampreloxetine, targeting symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA). This condition affects approximately 80% of MSA patients, leading to severe symptoms like dizziness and fainting. The study aims to address the unmet need for effective nOH treatments, with topline results expected in Q1 2026. If successful, ampreloxetine could become the first therapy to provide durable benefits for the estimated 40,000 U.S. patients with MSA-related nOH, potentially transforming treatment options in this underserved market.

The most recent analyst rating on (TBPH) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Spark’s Take on TBPH Stock

According to Spark, TipRanks’ AI Analyst, TBPH is a Neutral.

Theravance Biopharma’s overall stock score is driven by strong technical momentum and positive earnings call highlights, including strategic financial transactions and product advancements. However, the high P/E ratio and profitability challenges weigh on the valuation and financial performance scores, respectively.

To see Spark’s full report on TBPH stock, click here.

More about Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines. The company leverages its expertise to develop treatments for serious medical conditions, including the FDA-approved YUPELRI® for chronic obstructive pulmonary disease (COPD).

Average Trading Volume: 310,783

Technical Sentiment Signal: Buy

Current Market Cap: $700.5M

For a thorough assessment of TBPH stock, go to TipRanks’ Stock Analysis page.